IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MARRA, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.932
AS - Asia 3.507
NA - Nord America 3.442
SA - Sud America 346
AF - Africa 101
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.362
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.269
DE - Germania 1.440
CN - Cina 999
IT - Italia 994
SG - Singapore 882
HK - Hong Kong 396
BD - Bangladesh 386
VN - Vietnam 305
SE - Svezia 298
GB - Regno Unito 281
BR - Brasile 267
RU - Federazione Russa 196
FR - Francia 183
IN - India 161
NL - Olanda 122
CA - Canada 104
FI - Finlandia 90
IE - Irlanda 72
JP - Giappone 67
TR - Turchia 60
ES - Italia 53
CI - Costa d'Avorio 46
KR - Corea 45
ID - Indonesia 44
MX - Messico 35
CH - Svizzera 34
PH - Filippine 29
PL - Polonia 25
AR - Argentina 24
TW - Taiwan 24
AT - Austria 23
AU - Australia 22
DK - Danimarca 22
BE - Belgio 16
SA - Arabia Saudita 16
UA - Ucraina 16
IQ - Iraq 13
NO - Norvegia 13
CL - Cile 12
EG - Egitto 12
ZA - Sudafrica 12
EC - Ecuador 11
PK - Pakistan 11
CO - Colombia 10
PE - Perù 9
TH - Thailandia 9
MY - Malesia 8
NZ - Nuova Zelanda 8
AE - Emirati Arabi Uniti 7
IR - Iran 7
JM - Giamaica 7
TN - Tunisia 7
GR - Grecia 6
IL - Israele 6
RO - Romania 6
TT - Trinidad e Tobago 6
UZ - Uzbekistan 6
AM - Armenia 5
CZ - Repubblica Ceca 5
ET - Etiopia 5
HR - Croazia 5
LU - Lussemburgo 5
SC - Seychelles 5
VE - Venezuela 5
DZ - Algeria 4
KE - Kenya 4
KZ - Kazakistan 4
LT - Lituania 4
MA - Marocco 4
PT - Portogallo 4
BB - Barbados 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
JO - Giordania 3
PR - Porto Rico 3
PS - Palestinian Territory 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
UY - Uruguay 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
LV - Lettonia 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BT - Bhutan 1
EE - Estonia 1
EU - Europa 1
MD - Moldavia 1
Totale 11.351
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.290
Ashburn 503
Singapore 432
Hong Kong 326
Dallas 289
Milan 251
San Jose 224
Santa Clara 215
Southend 180
Hefei 168
Chandler 161
Los Angeles 161
Council Bluffs 126
Beijing 123
New York 94
Ho Chi Minh City 88
Fairfield 80
Boardman 77
Rome 73
Dublin 72
Hanoi 64
Helsinki 61
Lauterbourg 51
Buffalo 50
Bengaluru 49
Princeton 48
Moscow 47
Abidjan 46
Cambridge 45
Shanghai 44
Houston 43
Woodbridge 38
Toronto 37
São Paulo 35
Wilmington 35
Guangzhou 33
Naples 33
Tokyo 31
Seattle 30
Istanbul 29
Seoul 28
Jakarta 27
Munich 25
Phoenix 25
Des Moines 23
Turin 22
Ann Arbor 21
Florence 20
Atlanta 19
Bologna 19
Boston 19
Redwood City 19
Amsterdam 18
Berlin 18
Cangzhou 18
Columbus 18
Hangzhou 18
Chicago 17
Da Nang 17
London 17
Paris 17
Lappeenranta 16
Shenyang 16
Taipei 15
Bari 14
Montreal 14
Nanjing 14
Vienna 14
Changsha 13
Denver 13
Düsseldorf 13
Hyderabad 13
Mexico City 13
Central District 12
Dearborn 12
Genoa 12
Mumbai 12
Orem 12
Rio de Janeiro 12
San Francisco 12
Wuhan 12
Fuzhou 11
Palermo 11
The Dalles 11
Turku 11
Zhengzhou 11
Madrid 10
Nuremberg 10
Verona 10
Washington 10
Zurich 10
Jinan 9
Lima 9
Manchester 9
San Diego 9
Tianjin 9
Brooklyn 8
Buenos Aires 8
Cairo 8
Charlotte 8
Totale 6.653
Salva come PNG Salva come JPEG
Nome #
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 786
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 534
Long-term disease-free survival in surgically-resected oral tongue cancer: a 10-year retrospective study 415
Recent advances in triple negative breast cancer: the immunotherapy era 351
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 344
Expression of tumor-associated antigens in breast cancer subtypes 330
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 284
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 277
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 254
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 251
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC) : An Italian, Multicenter, Retrospective Study 246
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 243
Are all cyclin-dependent kinases 4/6 inhibitors created equal? 239
Evolution of low HER2 expression between early and advanced-stage breast cancer 225
Master protocols in immuno-oncology : Do novel drugs deserve novel designs? 221
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 211
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 210
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 209
T cell Bispecific Antibodies to Bypass MHC Class I Loss in Breast Cancer 206
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 201
What therapies are on the horizon for HER2 positive breast cancer? 201
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 197
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 190
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 185
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study 182
HER2-Low Breast Cancer: Pathological and Clinical Landscape 182
The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma : a Comprehensive Review 178
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 177
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy 177
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? 167
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 166
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region 163
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 158
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 155
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 151
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 147
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 147
Molecular tumor board in patients with metastatic breast cancer 146
Breast implant-associated anaplastic large cell lymphoma: A comprehensive review 139
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer 138
Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer 135
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 134
Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer 134
Pharmacological management of male breast cancer 130
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality 123
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 122
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 121
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer 119
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis 115
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 111
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 105
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 102
PARP Inhibitors for Breast Cancer Treatment 94
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer 83
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 74
Toward precision medicine in inflammatory breast cancer 72
EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials 66
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility 64
Conditional Generative AI in Oncology Diagnostics 21
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer 20
Artificial Intelligence in Thyroid Cytopathology: Diagnostic and Technical Insights 17
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study 17
Benchmarking foundation models as feature extractors for weakly supervised computational pathology 17
Advancing breast cancer therapy in the era of molecular diagnostics 16
Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer 15
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives 15
High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer 15
Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models 15
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy 14
APOBEC3 mutagenesis drives therapy resistance in breast cancer 14
KIT genetic alterations in breast cancer 14
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications 12
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2 12
Converging and evolving immuno-genomic routes toward immune escape in breast cancer 12
Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations 11
Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma 11
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 11
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma 10
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers 10
Genomic landscape of breast cancer in elderly patients 10
Molecular tumour board in gastrointestinal cancers 10
A Genomics-Driven Artificial Intelligence–Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms 9
Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity? 9
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series 9
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: A case report and review of the literature 9
Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization 9
High-throughput molecular assays for inclusion in personalised oncology trials – State-of-the-art and beyond 9
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome 8
The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features 8
Development and Validation of a Natural Language Processing Algorithm for Extracting Clinical and Pathological Features of Breast Cancer from Pathology Reports 8
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation 8
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer 8
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives 8
RB1 Genetic Alterations in Estrogen Receptor–Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation 8
Cancer-Causative Mutations Occurring in Early Embryogenesis 7
Immune checkpoint inhibitors in melanoma and HIV infection 7
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations 7
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions 7
ESMO basic requirements for AI-based biomarkers in oncology (EBAI) 7
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas 7
Totale 11.758
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.549
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022704 72 87 44 62 49 49 24 42 95 41 42 97
2022/2023706 84 78 67 66 46 102 25 61 79 12 70 16
2023/20241.477 34 49 42 62 117 86 223 179 87 174 202 222
2024/20252.126 192 213 178 193 91 73 51 199 106 226 202 402
2025/20265.701 514 509 615 415 300 221 666 213 389 303 614 942
2026/2027298 298 0 0 0 0 0 0 0 0 0 0 0
Totale 11.832